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Abstract
Background: Most clinical trials of direct-acting antiviral (DAA) therapy for hepatitis 
C virus (HCV) infection have excluded hepatitis B virus (HBV) coinfection, and little is 
known about the effects of DAA on chronic hepatitis C patients with HBV coinfection. 
Recent studies have reported that DAA therapy for HCV can also cause HBV reactivation 
in patients with HBV and HCV coinfection. The aim of this study was to assess the effects 
of DAA on sustained virologic response (SVR) and HBV reactivation in patients with 
chronic hepatitis C. Methods: Participants comprised 199 chronic hepatitis C patients 
who received DAA therapy (96 men, 103 women; mean age, 66.7 ± 12.0 years). Results: 
Twelve patients were coinfected with HCV and HBV. Sixty patients were HBV surface 
antigen negative but positive for hepatitis B core antibody and/or hepatitis B surface anti-
body, and one hundred and twenty-seven patients had not been exposed to HBV. Rates 
of SVR in HBV and HCV coinfected patients, HBV prior infection, and no exposure to 
HBV were 100, 95, and 97%, respectively. Significant differences were seen between each 
group. No case showed HBV reactivation. Conclusions: DAA treatments were effective 
in patients with HBV coinfection or HBV prior infection, as well as HCV monoinfection. 
As the number of cases was small, we still suggest caution regarding HBV reactivation in 
HCV and HBV coinfected patients undergoing treatment with DAA.
Keywords: HBV reactivation, hepatitis C virus, hepatitis B virus, sustained virologic 
response, direct-acting antiviral
© 2017 The Author(s). Licensee InTech. Distributed under the terms of the Creative Commons Attribut on-
NonCommercial 4.0 License (https://creativecommons.org/l censes/b -nc/4 0/), which permits use, distribution
and reproduction for non-commercial purposes, provided the original is properly cited.
1. Introduction
An estimated 170 million individuals worldwide are infected with hepatitis C virus (HCV), 
causing chronic hepatitis that can develop into potentially fatal cirrhosis and hepatocellular car-
cinoma [1]. HCV infection is therefore a major global health problem. Since 1992, interferon (IFN)-
based therapies have represented the gold standard of treatment for HCV infection. However, 
sustained virologic response (SVR) from IFN-based therapy is insufficient for all patients, espe-
cially those with HCV genotype 1 or cirrhosis and the elderly. In addition, IFN-based therapy 
is associated with numerous adverse events, such as fatigue, headache, nausea, insomnia, loss 
of appetite, influenza-like illness, chills, pyrexia, rash, pruritus, anemia or neutropenia, mental 
disorder, and thyroid dysfunction. To overcome these problems, IFN-free regimens have been 
developed and are now becoming the standard of care. Daclatasvir plus asunaprevir was the 
first IFN-free regimen to become commercially available in Japan for patients with HCV geno-
type 1b, from 2014 [2]. Several IFN-free regimens have become available for daily practice, and 
most studies have demonstrated high SVR rates and good safety outcomes [3, 4]. Some IFN-free 
regimens have demonstrated favorable safety and high efficacy within clinical trials among dif-
ficult-to-treat patients such as patients who have experienced DAA treatment, cirrhosis, chronic 
kidney disease, Human immunodeficiency virus co-infection, those on opiate agonist therapy, 
and patients with liver transplant [5–10]. However, most clinical trials of IFN-free therapy for 
chronic hepatitis C have excluded hepatitis B virus (HBV) coinfection. Few questions remain 
unanswered for IFN-free regimens, but little is known about the effects of DAA on SVR and 
HBV reactivation among chronic hepatitis C patients with HBV coinfection. Reactivation of HBV 
in HBV surface antigen (HBsAg)–positive patients treated with immunosuppressive or cytotoxic 
chemotherapy is well known and has emerged as an important clinical issue [11, 12]. HBV reac-
tivation can be caused not only by immunosuppressive or cytotoxic chemotherapy but also by 
DAA, with some studies reporting HBV reactivation in patients with HBV and HCV coinfection 
treated by DAA therapy for HCV [13–16]. In addition, although the risk is low, HBV reactivation 
in patients with resolved HBV infection—that is, in patients negative for HBsAg but positive for 
hepatitis B core antibody (HBcAb) and/or hepatitis B surface antibody (HBsAb)—can also occur 
[17]. HBV reactivation should thus be considered in HCV patients with not only HBV infection 
but also HBV prior infection treated using DAA therapy. However, little is known about HBV 
reactivation in chronic hepatitis C patients who have received DAA therapy or the relationship 
between SVR and HBV coinfection. The aim of this study was to assess the effects of DAA on 
HBV reactivation in patients with HBsAg-positive status or HBV prior infection, and whether 
HBV infection affects SVR.
2. Methods
2.1. Subjects
A total of 199 patients with chronic hepatitis C who had received DAA therapy were enrolled 
retrospectively, comprising 96 men and 103 women (mean age, 66.7 ± 12.0 years). Patients with 
Child Pugh classification B and C were excluded. No patient had autoimmune disease or chronic 
alcohol abuse. Prior to DAA therapy, HBsAg was measured for all patients. Patients showing 
Update on Hepatitis C42
HBsAg also underwent measurement of HBsAb and HBcAb. Patients were classified by HBV 
infection status. Patients with HBs Ag were regarded as HBV + HCV group, and patients were 
positive for HBcAb and/or HBsAb were regarded as prior infection group, and patients without 
any of HBsAg, HBcAb, or HBsAb were regarded as no exposure group. Eighty patients were 
treated with ledipasvir-sofosbuvir, 100 patients were treated using asunaprevir and daclatasvir, 
and 19 patients were treated with sofosbuvir and ribavirin. Patients who were persistently neg-
ative for serum HCV-RNA at 12 weeks after withdrawal of DAA treatment were considered to 
have shown SVR. Investigation of HBV reactivation was performed during and 12 months after 
the end of DAA treatment. This study was approved by the Nagoya University Hospital ethics 
committee. Written informed consent was obtained from each patient, and the study protocol 
conformed to the ethical guidelines of the Declaration of Helsinki.
2.2. Statistical analyses
Data are expressed as mean ± standard deviation. Contingency table analysis with Fisher's 
exact probability test was used for comparisons between groups. Values of p < 0.05 were 
considered statistically significant. Analyses were conducted using SPSS version 23 software 
(IBM, New York, NY).
3. Results
Twelve patients were positive for HBsAg and defined as showing chronic hepatitis C with 
HBV coinfection. A total of 187 patients were negative for HBsAg, but 65 patients were posi-
tive for HBcAb and/or HBsAb. Five of the sixty-five patients had received HBV vaccination 
HBV + HC Prior infection No exposure
N = 12 N = 60 N = 127
Age (y.o.) 64.2 ± 6.8 68.7 ± 9.5 65.7 ± 13.0
Sex: M/F 10/2 30/30 56/71
AST (IU/L) 45.6 ± 36.7 44.3 ± 21.1 49.3 ± 27.0
ALT (IU/L) 56.2 ± 44.1 38.8 ± 19.9 49.4 ± 36.5
Platelet (104/uL) 12.5 ± 5.0 15.2 ± 5.2 15.5 ± 7.1
HCV-RNA level (log IU/mL) 5.9 ± 0.8 6.1 ± 1.1 6.2 ± 0.9
HCV genotype (1/2) (11/1) (54/6) (115/12)
DAA (ASV + DCV/SOF + RBV/LDV + SOF) (5/1/6) (28/6/26) (67/12/48)
SVR 12 (100%) 57 (95%) 123 (97%)
HBV reactivation none none none
HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; DAA, 
direct-acting antiviral; ASV, asunaprevir; DCV, daclatasvir; SOF, sofosbuvir; RBV, ribavirin; LDV, ledipasvir; SVR, 
sustained virologic response.
Table 1. Clinical characteristics.
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Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9 Case 10 Case 11 Case 12
Age 66 54 70 61 70 56 70 55 66 69 59 74
Sex M M F M M M M F M M M M
ALT(IU/L) 27 38 164 29 31 87 70 111 19 28 39 31
HCV RNA (log IU/ml) 7.0 5.8 5.7 5.3 5.7 7.1 5.3 4.1 6.3 6.6 5.6 6.2
HCV genotype 2a 1b 1b 1b 1b 1b 1b 1b 1b 1b 1b 1b
























HBV DNA (log copy/mL) 2.1 0 2.1 2.1 2.8 4.5 0 4.7 3.3 ND ND ND
HBs Ag titer (lU/mL) 23 3 43 100 250 3.5 539 63 6 11 11 14
HBeAb Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive Positive
Treat for HBV None ETV ETV None None ETV ETV None None None None None
HBV genotype ND C ND ND ND B ND C ND ND ND ND
SVR Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Reactivation None None None None None None None None None None None None
HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; DAA, direct-acting antiviral; ASV, asunaprevir; DCV, 
daclatasvir; SOF, sofosbuvir; RBV, ribavirin; LDV, ledipasvir; SVR, sustained virologic response; ND, not done; ETV, entecavir.
Table 2. Clinical characteristics of patients with HBV and HCV coinfection.
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and were thus excluded from being considered as showing previous HBV infection; as a result, 
sixty patients were defined as having prior infection with HBV. The remaining 122 patients 
were not positive for any of HBsAg, HBcAb, or HBsAb. With the addition of the 5 vaccinated 
patients, a total of 127 patients were defined as showing no exposure to HBV. Clinical charac-
teristics at baseline and outcomes such as SVR and incidence of HBV reactivation according 
to HBV infection status are shown in Table 1. No significant differences in clinical character-
istics including age, sex, alanine aminotransferase, platelet count, HCV genotypes, and HCV 
viral load were evident between these three groups. SVR rate in HBV and HCV coinfected 
patients, HBV prior infection, and no exposure to HBV were 100, 95, and 97%, respectively. 
No significant differences in SVR were seen between groups. No cases representing definitive 
HBV reactivation were seen during and after DAA treatment. Clinical characteristics of the 
12 patients with HBV and HCV coinfection are shown in Table 2. Concentrations of HBsAg 
were less than 100 IU/mL in most cases, and all titers of HBV-DNA were less than 5 log cop-
ies/mL. All patients were positive for hepatitis B e antibody (HBeAb). Four patients received 
entecavir (ETV) before DAA therapy.
4. Discussion
With the advent of novel agents for chemotherapy and immunotherapy, insufficient data 
have been accumulated regarding the incidence of HBV reactivation. The association between 
novel agents and HBV reactivation was noteworthy. At first glance, DAA therapy appears 
safe, since no HBV reactivation has been observed in several clinical trials. However, most 
clinical trials of DAA therapy for HCV infection have excluded patients with HBV coinfec-
tion, and this bias would obviously mask the incidence of HBV reactivation due to DAA 
therapy. Real-world experience has revealed HBV reactivation in patients with chronic 
hepatitis C treated using all-oral direct-acting antiviral regimens [13–16]. In the era of IFN-
based therapy against HCV infection, HBV reactivation was not a noteworthy phenomenon 
for chronic hepatitis C. However, in the era of DAA therapy against HCV infection, HBV 
reactivation should be a concern in the treatment of patients with HCV infection. IFN rarely 
induces HBV reactivation, because IFN acts on both HBV and HCV, whereas DAAs act only 
on HCV. Viral interference between HCV and HBV is known to occur and HCV infection 
may suppress HBV replication. Rapid eradication of HCV by DAA would thus promote HBV 
replication and subsequent HBV reactivation. The small number of the total cohort and lack 
of incidence of HBV reactivation is of major concern for this study. Twelve patients infected 
with HBV and HCV were observed, and no cases showed definitive HBV reactivation during 
or after DAA treatment. Wang et al. reported that of 317 patients enrolled, 3 of the 10 patients 
with HBsAg showed HBV reactivation [18]. However, another study reported no evidence of 
HBV reactivation among patients treated with ledipasvir-sofosbuvir [19]. HBV reactivation 
thus remains controversial. Wang et al. speculated that DAAs, particularly NS3 polymerase 
inhibitors, carry a high risk of HBV reactivation because most reports of HBV reactivation 
related to DAA involved NS3 polymerase inhibitors [13, 14, 16, 18]. Ledipasvir is a NS5A 
replication complex inhibitor, and sofosbuvir is a NS5B polymerase inhibitor. The regimen 
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with ledipasvir-sofosbuvir did not use NS3 polymerase inhibitors, which may be why their 
study found no cases of HBV reactivation. HBV reactivation induced by ledipasvir-sofosbuvir 
has been reported, in a patient infected with HIV who was receiving antiretroviral therapy 
including tenofovir [15]. However, that patient discontinued tenofovir because of osteopo-
rosis 14 months before the onset of HBV reactivation. The effects of discontinuing tenofovir 
would thus have been relevant in that case. Further studies are needed to clarify whether 
HBV reactivation may occur irrespective of the class of DAA used. Another hypothesis that 
could explain the lack of HBV reactivation in this study was that the efficacy of prophylactic 
treatment with a nucleotide analog in preventing HBV reactivation among patients with HBV 
infection during and after chemotherapy and immunotherapy is well known. Four of twelve 
patients had received ETV before DAA therapy in our study and ETV would work as pre-
emptive therapy in reducing the incidence of HBV reactivation. A second hypothesis for the 
absence of HBV reactivation in this study involves HBV status. All patients were negative for 
hepatitis B e antigen (HBeAg) and HBV-DNA titers were less than 5 log copies/mL. Several 
risk factors for HBV reactivation have been identified, including HBeAg positivity and high 
HBV DNA levels [20–22]. Thus, the majority of patients enrolled in our study were low-risk 
patients with HBeAg-negative status and low titers of HBV DNA.
We did not evaluate HBV genotypes in all patients because of low levels of both HBV DNA and 
HBsAg, but all our patients were Japanese, and we presumed the most prevalent types would 
be genotype B or C.
Two billion people have been exposed to HBV worldwide, and our study indicates that 
one-third of patients with HCV infection were defined as showing prior HBV infection. 
Most countries perform universal vaccination to prevent HBV infection, but only high-risk 
groups such as health care workers and household contacts of HBV carriers are selected for 
HBV vaccination in Japan [23]. Vaccinated patients were easily distinguished from those 
with resolved HBV infection in this study. Rituximab has become the standard of care for 
patients with malignant lymphoma, and HBV reactivation has also been reported in lym-
phoma patients with prior HBV infection [17]. A low level of HBV is well recognized as per-
sisting in the liver and peripheral blood mononuclear cells in patients with resolved HBV 
infection and a functioning immune system. Immunosuppressive agents or chemotherapy 
may block the immune functions that suppress HBV replication, thus accelerating HBV rep-
lication. HBV reactivation thus occurred in patients with prior HBV infection. The incidence 
of HBV reactivation in patients with chronic hepatitis C treated by DAAs among patients 
with prior HBV infection is not yet fully understood, but we speculate that DAAs lead to 
HBV reactivation in patients with resolved HBV infection. However, we failed to identify 
any cases representing HBV reactivation among patients with resolved HBV infection in this 
study. We have previously report a case of acute hepatitis B in a patient with HCV infection 
after DAA therapy [16]. However, the presence of HBcAb or HBsAb was not determined 
before DAA therapy, so prior HBV infection status was unclear. This case is speculated to 
represent HBV reactivation in a patient with previously resolved HBV induced by DAA 
therapy, based on virologic analysis and clinical status. Amino acid substitutions in the S 
region as immune escape mutants and minority patterns for HBV genotype and serologi-
cal subtype were virologic features of HBV reactivation [24, 25]. DAAs were suspected to 
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induce HBV reactivation, and effective strategies to prevent HBV reactivation are needed. 
However, data on the incidence of HBV reactivation with DAA therapy are limited. Larger 
studies are needed to establish whether the risk of HBV reactivation is increased during and 
after DAA therapy.
Several factors have been identified, including age, liver fibrosis, HCV genotype, HCV RNA 
levels, race, amino acid substitutions in the core and NS5A regions, and interleukin 28B 
polymorphisms have been reported as predictors of response to IFN therapy [26–31]. This 
study investigated whether HBV coinfection affects response to DAA therapy. However, 
HBV infection was not associated with SVR from DAA therapy. DAA could eradicate over 
95% of HCV, and identification of predictors for SVR is difficult. The limitation of the pres-
ent study was the small sample size, and larger prospective cohorts are needed to confirm 
our results.
In conclusion, although relatively few cases have been reported in the literature, we suggest 
caution regarding HBV reactivation in HCV and HBV coinfected patients undergoing treat-
ment with DAA.
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